Shanghai Moyom Biotech

Shanghai Moyom Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative small molecule therapeutics for cancer. The company leverages its expertise in the ubiquitin-proteasome system and DNA damage response (DDR) to target specific vulnerabilities in tumor cells. Its lead candidate, MY-001, is a highly selective USP1 inhibitor that has entered Phase 1 clinical trials in both the United States and China for the treatment of advanced solid tumors. Moyom Biotech is backed by prominent venture capital firms, including HighLight Capital and Qiming Venture Partners, and continues to advance a pipeline of novel oncology programs. The company aims to provide transformative treatments for patients with high unmet medical needs in the oncology space.